CNT-EMG-02

CNT-EMG-02 is a small molecule therapeutic candidate currently in development by **Centurion Pharma** (Centurion İlaç) for the treatment of cardiovascular conditions. The drug is specifically designed as a self-injection system formulation, suggesting an application in emergency or acute care settings where rapid administration is critical. While the specific active pharmaceutical ingredient has not been publicly disclosed, the 'EMG' prefix in the sponsor code typically denotes emergency-use products within Centurion's pipeline, which also includes related programs CNT-EMG-03 and CNT-EMG-04. The program is part of Centurion's broader R&D focus on value-added medicines and advanced delivery systems.